Chemotherapy by slowing glucosphingolipid synthesis

Biochemical Pharmacology

Volumn 57, Issue 6, 1999, Pages 589-595

  Radin, Norman S ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b NONE   (United States)

Author keywords

Cancer; Diabetic hypertrophy; Glucosylceramide synthase inhibitors; Immunosuppression; Infection limitation; Multidrug resistance; Proliferation; Sphingolipidoses

Indexed keywords

BOTULINUM TOXIN; GLUCOSYLCERAMIDE; GLYCOSPHINGOLIPID;

CHEMOTHERAPY; DIABETES MELLITUS; DRUG DESIGN; GAUCHER DISEASE; HUMAN; INFECTION; LIPOGENESIS; METASTASIS INHIBITION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0033560130     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(98)00274-3     Document Type: Note

References (33)

1. 1. Radin NS, Treatment of Gaucher disease with an enzyme inhibitor. Glyconj J 13: 153-157, 1996.
2. 2. Platt FM, Neises GR, Reinkensmeier G, Townsend MJ, Perry VH, Proia RL, Winchester B, Dwek RA and Butters TD, Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. Science 276: 428-431, 1997.
3. 3. Hollak CEM, Evers L, Aerts JMFG and Van oers MHJ, Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease. Blood Cells Mol Dis 23: 201-212, 1997.
4. 4. Shayman JA, Deshmukh G, Mahdiyoun S, Thomas TP, Wu D, Barcelon FS and Radin NS, Modulation of renal epithelial cell growth by glucosylceramide: Association with protein kinase C, sphingosine, and diacylglyceride. J Biol Chem 266: 22968-22974, 1991.
5. 5. Marsh NL, Elias PM and Holleran WM, Glucosylceramides stimulate murine epidermal hyperproliferation. J Clin Invest 95: 2903-2909, 1995.
6. 6. Hara A and Radin NS, Enzymic effects of β-glucosidase destruction in mice. Changes in glucuronidase levels. Biochim Biophys Acta 582: 423-433, 1979.
7. 7. Inokuchi J, Mason I and Radin NS, Antitumor activity in mice of an inhibitor of glycosphingolipid biosynthesis. Cancer Lett 38: 23-30, 1987.
8. 8. Saha S and Chattopadhyay U, Changes in plasma gangliosides in relation to tumor growth and their tumor-enhancing effect. Int J Cancer 41: 432-435, 1988.
9. 9. Datta SC and Radin NS, Stimulation of liver growth and DNA synthesis by glucosylceramide. Lipids 23: 508-510, 1988.
10. 10. Shukla A, Shukla GS and Radin NS, Control of kidney size by sex hormones; Possible involvement of glucosylceramide. Am J Physiol 262: F24-F29, 1992.
11. 11. Zador IZ, Deshmukh GD, Kunkel R, Johnson K, Radin NS and Shayman JA, A role for glycosphingolipid accumulation in the renal hypertrophy of streptozotocin-induced diabetes mellitus. J Clin Invest 91: 797-803, 1993.
12. 12. Chatterjee S, Lactosylceramide stimulates aortic smooth muscle cell proliferation. Biochem Biophys Res Commun 181: 554-561, 1991.
13. 13. Usuki S, Hamanoue M, Kohsaka S and Inokuchi J-I, Induction of ganglioside biosynthesis and neurite outgrowth of primary cultured neurons by L-threo-1-phenyl-2-de-canoylamino-3-morpholino-1-propanol. J Neurochem 67: 1821-1830, 1996.
14. 14. Kaucic K, Grovas A, Li R, Quinones R and Ladisch S, Modulation of human myelopoiesis by human gangliosides. Exp Hematol 22: 52-59, 1994.
15. 15. Dozmorov IM, Prokhazova AL, Svirtshevskaya EV, Lutsan NI, Kozin II, Lemenovskaya AD, Dyatlovitskaya EV and Bergelson LD, Nanomolar concentrations of gangliosides stimulate primary humoral response. Biochem Mol Biol Int 42: 57-63, 1997.
16. 16. Vuist WMJ, Van Schaik IN, Van Lint M and Brand A, The growth arresting effect of human immunoglobulin for intravenous use is mediated by antibodies recognizing membrane glycolipids. J Clin Immunol 17: 301-310, 1997.
17. 17. Radin NS and Inokuchi J, Glucosphingolipids as sites of action in the chemotherapy of cancer. Biochem Pharmacol 37: 2879-2886, 1988.
18. 18. Hakomori S, Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res 56: 5309-5318, 1996.
19. 19. Deshmukh GD, Radin NS, Gattone VH II and Shayman JA, Abnormalities of glycosphingolipid, sulfatide, and ceramide in the polycystic (cpk/cpk) mouse. J Lipid Res 35: 1611-1618, 1994.
20. 20. Chang FM, Li RX and Ladisch S, Shedding of gangliosides by human medulloblastoma cells. Exp Cell Res 234: 341-346, 1997.
21. 21. Ravindranath MH and Morton DL, Role of gangliosides in active immunotherapy with melanoma vaccine. Int Rev Immunol 7: 303-329, 1991.
22. 22. Chu JWK and Sharom FJ, Gangliosides inhibit T-lymphocyte proliferation by preventing the interaction of interleukin-2 with its cell surface receptors. Immunology 79: 10-17, 1993.
23. 23. Olshefski R and Ladisch S, Synthesis, shedding, and intercellular transfer of human medulloblastoma gangliosides: Abrogation by a new inhibitor of GlcCer synthase. J Neurochem 70: 467-472, 1998.
24. 3 and ceramide reduce the invasion of tumor cells through extra-cellular matrix components by elevating protein phosphatase-2A. Invasion Metastasis 16: 280-290, 1997.
25. 2) better than soluble lysate cancer vaccine. Anticancer Drugs 8: 217-224, 1997.
26. 3H]PDMP, an inhibitor of glucosylceramide synthesis, and the synergistic action of an inhibitor of microsomal monooxygenase. J Lipid Res 32: 713-722, 1991.
27. 27. Lucci A, Cho WI, Han TY, Giuliano AE, Morton DL and Cabot MC, Glucosylceramide: A marker for multiple-drug resistant cancers. Anticancer Res 18(1B): 475-480, 1998.
28. 28. Lavie Y, Cao H, Volner A, Lucci A, Han T-Y, Geffen V, Giuliano AE and Cabot MC, Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells. J Biol Chem 272: 1682-1687, 1997.
29. 2 antibody. Int J Cancer 67: 676-680, 1996.
30. 30. van Helvoort A, Smith AJ, Sprong H, Fritsche I, Schinkel AH, Borst P and van Meer G, MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell 87: 507-517, 1996.
31. 31. Inokuchi J, Jimbo M, Momosaki K, Shimeno H, Nagamatsu A and Radin NS, Inhibition of experimental metastasis of murine Lewis lung carcinoma by an inhibitor of glucosylceramide synthase and its possible mechanism of action. Cancer Res 50: 6731-6737, 1990.
32. 32. Svensson M, Lindstedt R, Radin NS and Svanborg C, Epithelial glucosphingolipid expression as a determinant of bacterial adherence and cytokine production. Infect Immun 62: 4404-4410, 1994.
33. 33. Ledeen RW, Hakomori S, Yates AJ, Schneider JS and Yu RK (Eds.), Sphingolipids as Signaling Modulators in the Nervous System. Annals of the New York Academy of Sciences, Vol. 845. The New York Academy of Sciences, New York, 1998.